Boundless Bio Inc 2025年度报告

120 days after the end of the fiscal year covered by this report are incorporated by reference into Part III of this report. Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of EquitySecurities91Item 6.[Reserved]91Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations92Item 7A.Quantitative and Qualitative Disclosures About Market Risk102Item 8.Financial Statements and Supplementary Data102Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure103Item 9A.Controls and Procedures103Item 9B.Other Information103Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections104 PART III Item 10.Directors, Executive Officers, and Corporate Governance105Item 11.Executive Compensation105Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters105Item 13.Certain Relationships and Related Transactions, and Director Independence105Item 14.Principal Accountant Fees and Services105 PART IV Item 15.Exhibits and Financial Statement Schedules106Item 16.Form 10-K Summary107 PART I SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND MARKET AND INDUSTRY DATA This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the SecuritiesAct of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the ExchangeAct). All statements other than statements of historical facts contained in this report are forward-looking statements, includingstatements regarding our future results of operations and financial position, our business strategy, research and development plans,the anticipated timing, costs, design, and conduct of our ongoing and planned clinical trials and preclinical studies for ourextrachromosomal DNA (ecDNA) directed therapeutic candidate (ecDTx), our use of the net proceeds from the initial publicoffering (IPO) of our common stock, the period over which we estimate our cash position will be sufficient to fund our operations,the sufficiency of our cash position to fund achievement of milestones, including initial clinical data readout, the expected benefits ofthe portfolio prioritizations we recently implemented, the timing and likelihood of success, plans, and objectives of management forfuture operations, the potential to enter into strategic collaborations, the timing of expected clinical data readout for our ecDTx, thepotential safety and therapeutic benefits of our ecDTx, the potential addressable patient populations for our ecDTx, the potential toidentify additional development opportunities for our ecDTx or expand our therapeutic pipeline, the timing and likelihood ofregulatory submissions, filings and approvals for our ecDTx, expected regulatory approval pathways for our ecDTx, our ability tocommercialize our ecDTx, if approved, the pricing and reimbursement of our ecDTx, if approved, potential competition for ourecDTx, our intellectual property and other market exclusivity strategies, our intent regarding any strategic collaborations, licenses, orsimilar arrangements and the potential benefits of any such arrangements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,”“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “would,” “target,” or“will” or the negative of these terms or other similar expressions. Our forward-looking statements are only predictions. We havebased our forward-looking statements largely on our current expectations and projections about future events and financial and othertrends that we believe may affect our business, financial condition, and results of operations based upon information available to usas of the date of this report. Such information may be limited or incomplete. Forward-looking statements in this report speak only asof the date of this report and are subject to several risks, uncertainties, and assumptions, including those described in Part I, Item 1,“Business,” and Item 1A, “Risk Factors,” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition andResults of Operations.” The events and circumstances reflected in our forward-looking statements may not be achieved or occur,and, our actual results, performance, or achievements could differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time totime, and it is not possible for management to predict all risk factors and uncertainties. Because forward-looking statements areinheren